ABVC BioPharma, Inc. (ABVC)
| Market Cap | 21.52M -69.3% |
| Revenue (ttm) | n/a |
| Net Income | -7.11M |
| EPS | -0.29 |
| Shares Out | 25.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,138 |
| Open | 0.8400 |
| Previous Close | 0.7957 |
| Day's Range | 0.8100 - 0.8499 |
| 52-Week Range | 0.7069 - 3.4000 |
| Beta | 0.63 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About ABVC
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ... [Read more]
Financial Performance
Financial StatementsNews
ABVC BioPharma Proxy statement: Proxy filing
ABVC BioPharma filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Proxy statement: Proxy filing
ABVC BioPharma filed a proxy statement on August 12, 2026, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Quarterly report: Q2 2026
ABVC BioPharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
ABVC Biopharma Inc trading halted, news pending
16:43 EDT ABVC Biopharma (ABVC) Inc trading halted, news pending
ABVC BioPharma Proxy statement: Proxy filing
ABVC BioPharma filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Quarterly report: Q1 2026
ABVC BioPharma has published its Q1 2026 quarterly earnings report on May 18, 2026.
ABVC BioPharma Proxy statement: Proxy Filing
ABVC BioPharma filed a proxy statement on March 5, 2026, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Annual report: Q4 2025
ABVC BioPharma has published its Q4 2025 annual report on March 3, 2026.
ABVC BioPharma Proxy statement: Proxy Filing
ABVC BioPharma filed a proxy statement on February 5, 2026, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Earnings release: Q3 2025
ABVC BioPharma released its Q3 2025 earnings on November 3, 2025, summarizing the period's financial results.
ABVC BioPharma Quarterly report: Q3 2025
ABVC BioPharma has published its Q3 2025 quarterly earnings report on November 3, 2025.
ABVC BioPharma Earnings release: Q2 2025
ABVC BioPharma released its Q2 2025 earnings on August 13, 2025, summarizing the period's financial results.
ABVC BioPharma Quarterly report: Q2 2025
ABVC BioPharma has published its Q2 2025 quarterly earnings report on August 13, 2025.
ABVC BioPharma files $100M mixed securities shelf
16:04 EDT ABVC BioPharma (ABVC) files $100M mixed securities shelf
ABVC BioPharma Registration statement: Registration Filing
ABVC BioPharma filed a registration statement on May 22, 2025, providing details about a securities offering with the SEC.
ABVC BioPharma Proxy statement: Proxy Filing
ABVC BioPharma filed a proxy statement on May 16, 2025, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Quarterly report: Q1 2025
ABVC BioPharma has published its Q1 2025 quarterly earnings report on April 29, 2025.
ABVC BioPharma Proxy statement: Proxy Filing
ABVC BioPharma filed a proxy statement on April 25, 2025, providing details for shareholder voting and corporate governance matters.
ABVC BioPharma Earnings release: Q4 2024
ABVC BioPharma released its Q4 2024 earnings on April 15, 2025, summarizing the period's financial results.
ABVC BioPharma Quarterly report: Q4 2024
ABVC BioPharma has published its Q4 2024 quarterly earnings report on April 15, 2025.
ABVC BioPharma Annual report: Q4 2024
ABVC BioPharma has published its Q4 2024 annual report on April 15, 2025.
ABVC BioPharma believes ABV-1504 can fill void in market after Prozac
ABVC BioPharma (ABVC) announced in response to the discontinuation of Prozac due to increasing concerns around side effects, ABVC believes its ABV-1504, which has the API, “Radix Polygala”, known as…
ABVC BioPharma receives $200,000 cash payment from OncoX
ABVC BioPharma (ABVC) announced the receipt of a $200,000 cash payment from OncoX BioPharma as part of its strategic licensing agreement for certain oncology-related products; this payment marks the f...
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervou...
ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year
Reports Q3 revenue $389,276 vs $15,884 last year. Improved Cash Position: The Company’s cash and cash equivalents reached $137,344 as of September 30, 2024, up from $60,155 at the end…